NorthAvenue LLC
VRTX icon

NorthAvenue LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

NorthAvenue LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$523 Hold
1
– – ﹤0.01% 232
2026
Q2 		$497 Hold
1
– – ﹤0.01% 269
2026
Q1 		$447 Hold
1
– – ﹤0.01% 237
2025
Q4 		$454 Buy
+1
New +$431 ﹤0.01% 280

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

NorthAvenue LLC's VRTX Position: Q3 2026 in Review

NorthAvenue LLC held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 1 share worth $523. The position accounts for ﹤0.01% of the portfolio, ranked #232.

NorthAvenue LLC first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 1,161 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • NorthAvenue LLC held 1 share of Vertex Pharmaceuticals worth $523 as of Q3 2026.
  • NorthAvenue LLC left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of NorthAvenue LLC's portfolio in Q3 2026, its #232 holding.
  • NorthAvenue LLC first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 1,161 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on NorthAvenue LLC's 13F filing for Q3 2026, filed 29 Oct 2026.